Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOv18 IgE in Solid Tumours Overexpressing Folate Receptor Alpha
NCT06547840Phase 1Recruiting
- Sponsor
- Epsilogen
- Start
- Sep 2024
- Primary completion
- Jul 2026
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MOv18 IgE in ovarian cancer, endometrial cancer (EC) and triple-negative breast cancer (TNBC), sponsored by Epsilogen. Primary endpoints: Safety and tolerability of MOv18 IgE at 1.5 years, Maximum Tolerated Dose or Maximum Administered Dose at 1.5 years and 2 more. Started Sep 2024; status: recruiting.
02
Drugs
MOv18 IgE
03
Conditions
ovarian cancerendometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06547840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547840.